Form 4: Cyclo Therapeutics Director C.E. Rick Strattan Receives Stock and Options

Director C.E. Rick Strattan received shares and options from Cyclo Therapeutics on June 3, 2024, according to a Form 4 filing.

Summary

• C.E. Rick Strattan, a director of Cyclo Therapeutics, Inc. (CYTH), reported changes in beneficial ownership on June 5, 2024.
• On June 3, 2024, Strattan acquired 9,375 shares of common stock as compensation in lieu of cash, valued at $0, based on a price of $1.28 per share.
• Strattan also acquired options to purchase 15,562 shares of common stock at an exercise price of $1.28, vesting over one year in equal quarterly installments and expiring on June 3, 2034.
• Following these transactions, Strattan beneficially owns 295,971 shares of common stock and options for 15,562 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of director compensation. The acquisition of shares and options by a director could be seen as a positive sign of confidence in the company's future, but it's not a major event.

Positives

• The acquisition of shares and options by a director could be seen as a positive sign of confidence in the company's future.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in the holdings of a director at Cyclo Therapeutics.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the director increasing their stake in the company.

Key Dates